Statins may reduce femoral osteolysis in patients with total Hip arthroplasty

Bibliographic Details
Title: Statins may reduce femoral osteolysis in patients with total Hip arthroplasty
Authors: Constantinos Roussos, Kenneth J. Rothman, Hermès Howard Miozzari, Anne Lübbeke, Guido Garavaglia, Alexis Bonvin, Pierre Hoffmeyer
Source: Journal of Orthopaedic Research, Vol. 31, No 5 (2013) pp. 814-20
Publisher Information: Wiley, 2012.
Publication Year: 2012
Subject Terms: Male, Hydroxymethylglutaryl-CoA Reductase Inhibitors/therapeutic use, Arthroplasty, Replacement, Hip, Comorbidity, Osteolysis, Cohort Studies, 03 medical and health sciences, Postoperative Complications, 0302 clinical medicine, Risk Factors, Humans, Femur, Longitudinal Studies, Registries, Hip Joint/drug effects/surgery, Aged, Aged, 80 and over, ddc:617, Femur/drug effects/surgery, Middle Aged, 3. Good health, Prosthesis Failure, Arthroplasty, Replacement, Hip/statistics & numerical data, Prosthesis Failure/drug effects, Postoperative Complications/drug therapy/epidemiology, Female, Hip Joint, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Osteolysis/drug therapy/epidemiology
Description: In experimental studies, statin use has been associated with reduction of osteoclastic activity and promotion of bone formation around implants. Moreover, a large clinical study recently reported a substantially reduced risk of revision for aseptic loosening among statin users with THA. Our objective was to evaluate the influence of statin use on the development of femoral osteolysis within 5 years after THA. We conducted a case‐cohort study including all THAs presenting with femoral osteolysis at the 5 year visit (cases) and compared them with those without osteolysis (controls). Cases and controls were identified from a cohort of primary THAs operated between 2001 and 2005. Seven hundred thirty‐five THAs were included, mean age 68 years. Five years after surgery osteolysis had developed around the femoral component of 40 THAs (5.4%). Ever‐use of statins was much less frequent among cases (5 of 40, 12.5%) than among controls (199 of 695, 28.6%). The crude risk ratio of femoral osteolysis among statin users was 0.36 (95% CI 0.14; 0.92). After adjusting for age, sex, activity level, BMI, diagnosis, bearing surface, and type of stem, the adjusted risk ratio was 0.38 (95% CI 0.15; 0.99). In conclusion, statin use was associated with a reduced risk of developing femoral osteolysis 5 years after THA. Statins may be useful for reducing the risk of implant failure following THA. © 2012 Orthopaedic Research Society. Published by Wiley Periodicals, Inc. J Orthop Res 31: 814–820, 2013
Document Type: Article
File Description: application/pdf
Language: English
ISSN: 1554-527X
0736-0266
DOI: 10.1002/jor.22262
Access URL: https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/jor.22262
https://pubmed.ncbi.nlm.nih.gov/23138498
https://pubmed.ncbi.nlm.nih.gov/23138498/
https://archive-ouverte.unige.ch/unige:30089
https://www.rti.org/publication/statins-may-reduce-femoral-osteolysis-patients-total-hip-arthroplasty
https://www.ndorms.ox.ac.uk/publications/686725
https://www.ncbi.nlm.nih.gov/pubmed/23138498
https://onlinelibrary.wiley.com/doi/abs/10.1002/jor.22262
https://archive-ouverte.unige.ch/unige:30089
Rights: Wiley Online Library User Agreement
Accession Number: edsair.doi.dedup.....82a2e8348e965b0eb5a563273d7a372c
Database: OpenAIRE
Description
ISSN:1554527X
07360266
DOI:10.1002/jor.22262